Ning Leng, Yichen Lu, Jane Fridlyand, Tiffany Tang, Ting Qi, Yingying Wei, Rodrigo Rojo Sanchez, Noah Simon, Gregory Alexander
{"title":"Model generalizability considerations in development and evaluation of SaMD.","authors":"Ning Leng, Yichen Lu, Jane Fridlyand, Tiffany Tang, Ting Qi, Yingying Wei, Rodrigo Rojo Sanchez, Noah Simon, Gregory Alexander","doi":"10.1080/10543406.2026.2729800","DOIUrl":null,"url":null,"abstract":"<p><p>Software as a Medical Device (SaMD) has been transforming medical practices by improving patient care with more precise and timely information. Key capabilities of SaMD are often powered by Artificial Intelligence (AI) algorithms. However, significant challenges arise in developing robust algorithms for SaMD, as these algorithms can perform well during development but poorly during pivotal validation studies. Due to the rapid advancement in medical research, data from new studies or real-world sources are likely to differ significantly from the legacy data used for development; with this, algorithms need to account for these potential data heterogeneity differences. This paper discusses the shortcomings of conventional cross-validation methods widely used in SaMD algorithm development and demonstrates model performance overestimation in the presence of data heterogeneity. To address this bias, we propose a simple and practical alternative: the leave-one-set-out (LOSO) cross-validation method. Additionally, we outline best practices for designing independent validation pivotal studies.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-13"},"PeriodicalIF":1.3000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2026.2729800","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Software as a Medical Device (SaMD) has been transforming medical practices by improving patient care with more precise and timely information. Key capabilities of SaMD are often powered by Artificial Intelligence (AI) algorithms. However, significant challenges arise in developing robust algorithms for SaMD, as these algorithms can perform well during development but poorly during pivotal validation studies. Due to the rapid advancement in medical research, data from new studies or real-world sources are likely to differ significantly from the legacy data used for development; with this, algorithms need to account for these potential data heterogeneity differences. This paper discusses the shortcomings of conventional cross-validation methods widely used in SaMD algorithm development and demonstrates model performance overestimation in the presence of data heterogeneity. To address this bias, we propose a simple and practical alternative: the leave-one-set-out (LOSO) cross-validation method. Additionally, we outline best practices for designing independent validation pivotal studies.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.